Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation (scholarly article by Nico Gagelmann et al published May 2019 in Haematologica)

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Q24563021

Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome

Q27028159

International scoring system for evaluating prognosis in myelodysplastic syndromes

Q28305247

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).

Q30313209

Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

Q30353404

Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation

Q33615619

Revised international prognostic scoring system for myelodysplastic syndromes

Q34639717

Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplasti

Q35146316

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies

Q35554703

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge

Q36920348

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

Q36920445

Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually.

Q36974379

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

Q37263146

Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation.

Q38442976

Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in Allogeneic Stem Cell Transplantation: Systematic Literature Review and Network Meta-Analysis

Q38597409

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation

Q42158416

Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation

Q42214333

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.

Q45955430

Maximizing the benefit of allogeneic stem cell transplantation in myelodysplastic syndromes

Q48583635

Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.

Q53094779

Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic-Cell Transplantation: a Systematic Review and Meta-Analysis.

Q54205989

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant

Q72940232

Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype

Q81769874

Myelodysplastic syndromes

Q87492688

P433

issue

P407

language of work or name

English